Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community

In June, Zulresso — the first and only medicine approved by the Food and Drug Administration to specifically treat postpartum depression — will hit the market. Sage Therapeutics, the maker of the drug, now hopes to win the fight against another major issue: The public's misconception about mental health.